{"id":"NCT02273180","sponsor":"Sanofi","briefTitle":"Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","officialTitle":"Six-Month, Randomized, Open-Label, Parallel-group Comparison of SAR342434 to HumalogÂ® in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine, With a 6-month Safety Extension Period","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10","primaryCompletion":"2015-12","completion":"2016-07","firstPosted":"2014-10-23","resultsPosted":"2018-01-18","lastUpdate":"2018-01-18"},"enrollment":507,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"SAR342434","otherNames":[]},{"type":"DRUG","name":"Humalog","otherNames":["Insulin Lispro"]},{"type":"DRUG","name":"Insulin glargine HOE901","otherNames":["Lantus"]}],"arms":[{"label":"SAR342434","type":"EXPERIMENTAL"},{"label":"Humalog","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate non-inferiority of SAR342434 versus Humalog in glycated haemoglobin A1c (HbA1c) change from baseline to Week 26 in participants with type 1 diabetes mellitus (T1DM) also using insulin glargine.\n\nSecondary Objectives:\n\nTo assess the immunogenicity of SAR342434 and Humalog in terms of positive/negative status and antibody titers at baseline and during the course of the study.\n\nTo assess the relationship of anti-insulin antibodies with efficacy and safety including during the safety extension.\n\nTo assess the efficacy of SAR342434 and Humalog in terms of proportion of participants reaching target HbA1c (\\<7%), Fasting plasma glucose (FPG), self-measured plasma glucose (SMPG) profiles, and insulin dose.\n\nTo assess safety of SAR342434 and Humalog.","primaryOutcome":{"measure":"Change in HbA1c From Baseline to Week 26","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"SAR342434","deltaMin":-0.42,"sd":0.051},{"arm":"Humalog","deltaMin":-0.47,"sd":0.05}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":13},"locations":{"siteCount":89,"countries":["United States","France","Germany","Hungary","Japan","Poland","Russia","Spain"]},"refs":{"pmids":["28722480"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":252},"commonTop":["Nasopharyngitis","Upper respiratory tract infection"]}}